BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
Open Access
- 20 January 2015
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 112 (4) , 688-692
Abstract
This study aimed to determine whether the BRCA1 haplotype was associated with trabectedin efficacy in soft-tissue sarcoma (STS) patients. We analysed BRCA1 single-nucleotide polymorphisms (SNPs) in tumour specimens from 135 advanced STS patients enrolled in published phase 2 trials or in a compassionate-use programme of trabectedin. Forty-four advanced STS patients treated with doxorubicin and 85 patients with localised STS served as controls. The 6-month nonprogression rate and overall survival (OS) were analysed according to BRCA1 haplotype using log-rank tests. A favourable BRCA1 haplotype (presence of at least one AAAG allele) was significantly associated with an improved 6-month nonprogression rate. It was the only variable significantly associated with OS. No correlations were found between outcomes for patients with localised or advanced STS treated with doxorubicin. The BRCA1 haplotype represents a potential DNA repair biomarker that can be used for the prediction of response to trabectedin in STS patients.Keywords
This publication has 24 references indexed in Scilit:
- Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use programBMC Cancer, 2013
- Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexityNature Medicine, 2010
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different SchedulesJournal of Clinical Oncology, 2009
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to ChemotherapyJournal of Clinical Oncology, 2004
- Improved survival in women with BRCA‐associated ovarian carcinomaCancer, 2003
- Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinomaCancer, 2003
- A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer: Table 1Journal of Medical Genetics, 2002
- Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathwaysInternational Journal of Cancer, 2001
- Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of actionEuropean Journal of Cancer, 2001